Roche drops bids for Illumina

Swiss pharmaceutical group Roche is no longer considering a bid for US gene-sequencing company Illumina, chairman Franz Humer was quoted as saying yesterday. “Illumina is definitely off the table. They were not willing to abandon the totally unrealistic price they were asking for. Roche does not do acquisitions that don’t create value,” he told Swiss paper SonntagsZeitung.